Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Obseva Sa (NQ: OBSV )

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Mar 22, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Obseva Sa

< Previous 1 2 3 4 5 6 Next >
18 Stocks Moving in Monday's Pre-Market Session
Gainers FGI Industries Ltd. (NASDAQ: FGI) rose 92.8% to $7.27 in pre-market trading after jumping 19% on Friday. The company, last week, priced its IPO at $6 per... 
Via Benzinga
7 Penny Stocks to Buy for January
These penny stocks look poised for a rally in January 2022 and can possibly deliver multi-fold returns in the next 12 months. 
Via InvestorPlace
33 Stocks Moving In Thursday's Mid-Day Session
Gainers Eargo, Inc. (NASDAQ: EAR) shares jumped 50.8% to $6.88 after the company announced the Department of Justice confirmed to it that the previously-announced criminal probe... 
Via Benzinga
The Daily Biotech Pulse: Lilly Strikes Neurological R&D Collaboration, Valneva Confirms Vaccine Timelines, Biohaven Gains On Strong Migraine Drug Sales
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Illumina Announces Co-Development Partnership With SomaScan For Accelerating... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Good morning, trader! Let's start off the day right with a look into some of the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
23 Stocks Moving in Thursday's Pre-Market Session
Gainers Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) rose 54.3% to $0.9490 in pre-market trading after declining more than 11% on Wednesday. Alterity Therapeutics Limited... 
Via Benzinga
7 of the Best Penny Stocks Under $3 for 2022 to Buy Now
Penny stocks under $3 are full of potential and potential pitfalls. These are relatively safe and worth your consideration. 
Via InvestorPlace
Why Are ObsEva Shares Trading Higher Today?
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending approval for ObsEva SA'... 
Via Benzinga
28 Stocks Moving In Friday's Mid-Day Session
Gainers Genfit SA (NASDAQ: GNFT) shares jumped 33.6% to $4.41 after the company, and Ipsen, announced an exclusive licensing agreement for elafibranor. X4 Pharmaceuticals, Inc... 
Via Benzinga
The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck Announces Publication Of Positive Data From Late-Stage Study Of Oral... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Good morning, investor! We're in the home stretch of the week as we tackle the biggest pre-market stock movers for Friday! 
Via InvestorPlace
20 Stocks Moving in Friday's Pre-Market Session
Gainers Genfit SA (NASDAQ: GNFT) rose 47.5% to $4.90 in pre-market trading. Ipsen and GENFIT reported an exclusive licensing agreement for Elafibranor. Spruce Biosciences, Inc. (... 
Via Benzinga
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage... 
Via Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative... 
Via Benzinga
Exposures Product Safety
10 Biggest Price Target Changes For Monday
Citigroup cut Merck & Co., Inc. (NYSE: MRK) price target from $105 to $85. Merck shares fell 2% to $77.55 in pre-market trading. Keybanc lowered Arista Networks, Inc. (... 
Via Benzinga
7 Hot Penny Stocks to Buy for December That Are Positioned to Pop
These penny stocks remain positioned to run upwards in the near term. Purchasing shares in December could quickly lead to profits. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, traders! We're getting right into the week with a breakdown of the biggest pre-market stock movers for Monday! 
Via InvestorPlace
Exposures Product Safety
20 Stocks Moving in Monday's Pre-Market Session
Gainers Astra Space, Inc. (NASDAQ: ASTR) rose 39.6% to $13.30 in pre-market trading after declining around 3% on Friday. Astra Space recently reported a Q3 loss of $0.06 per... 
Via Benzinga
ObsEva Shares Jump After Linzagolix Application For Uterine Fibroids Goes Under FDA Review
The FDA has accepted for review ObsEva SA's (NASDAQ: OBSV) marketing application for linzagolix to manage heavy menstrual bleeding associated with uterine... 
Via Benzinga
Exposures Product Safety
7 Penny Stocks to Book Profits on Before 2022
Penny stocks can turn a quick profit. These 7 picks are designed to do so before the end of this year and cover multiple sectors. 
Via InvestorPlace
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) rose 143.5% to $15.83 in pre-market trading after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) rose 72.6% to $4.09... 
Via Benzinga
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer Review
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novavax Shares React to Reports Of Manufacturing Issues With Its COVID-19... 
Via Benzinga
ObsEva Presents Linzagolix Data From Uterine Fibroid Trials
ObsEva SA (NASDAQ: OBSV) has announced data from PRIMROSE (1 and 2) Phase 3 study of linzagolix for uterine fibroids. The data were presented at the American... 
Via Benzinga
The Daily Biotech Pulse: FDA Nod For Lilly, Regulus Slumps On Study Discontinuation, ObSeva Strikes Linzagolix Commercialization Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Revance Clarifies Gabellar Line Treatment Review On Track Responding to the... 
Via Benzinga
Exposures Product Safety
26 Stocks Moving in Wednesday's Pre-Market Session
Gainers Nxt-ID, Inc. (NASDAQ: NXTD) rose 46.1% to $0.6699 in pre-market trading after dropping 11% on Tuesday. MeaTech 3D Ltd. (NASDAQ: MITC) rose 18.5% to $6.29 in pre-market... 
Via Benzinga
ObsEva Files US Application For Linzagolix For Uterine Fibroids
ObsEva SA (NASDAQ: OBSV) has submitted a marketing application to the FDA seeking approval for linzagolix for uterine fibroids. Linzagolix is an oral GnRH receptor... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 14) Alcon Inc. (NYSE: ALC)... 
Via Benzinga
Exposures COVID-19
44 Stocks Moving In Tuesday's Mid-Day Session
Gainers Oragenics, Inc. (NASDAQ: OGEN) surged 55.9% to $0.9749 after the company announced it entered into a licensing agreement with the National Research Council of Canada that... 
Via Benzinga
The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 3) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
62 Biggest Movers From Yesterday
Gainers Intrusion Inc. (NASDAQ: INTZ) shares surged 52.1% to settle at $5.14 on Tuesday. Intrusion recently issued worse-than-expected preliminary Q2 sales results and announced... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.